Itolizumab reduces urine protein levels in Phase 1B clinical trial

Treatment with the investigational injection therapy itolizumab significantly reduced urine protein levels, a marker of kidney dysfunction, in people with active lupus nephritis, a serious lupus complication marked by kidney damage and inflammation. That’s according to top-line results from a Phase 1b trial called EQUALISE (NCT04128579) that were…

Trial will test AlloNK for SLE patients with lupus nephritis

AlloNK, an off-the-shelf experimental natural killer (NK) cell therapy being developed by Artiva Biotherapeutics, soon will enter clinical testing, in combination with rituximab, for systemic lupus erythematosus (SLE) patients with active lupus nephritis. This follows the approval of the company’s investigational new drug application by the U.S.

Lupkynis approved in Switzerland to treat adults with lupus nephritis

Lupkynis (voclosporin) is now approved in Switzerland to treat adults with active lupus nephritis, a complication of lupus characterized by kidney damage and inflammation. The approval specifically covers the treatment, given along immunosuppressants, for adults with active class 3, 4, and 5 lupus nephritis — three subtypes of the…

Long-term safety of Lupkynis for SLE confirmed in AURORA trial

Over 18 months, the approved therapy Lupkynis (voclosporin) lessened inflammation and prevented further kidney damage in systemic lupus erythematosus (SLE) patients with active lupus nephritis, without any signs of kidney-related toxicity seen with similar treatments. New top-line data show participants in the Lupkynis treatment arm of the now…

Lupkynis Approved in UK to Treat Adults With Active Lupus Nephritis

Lupkynis (voclosporin) has been approved in Great Britain as a treatment for adults with active lupus nephritis by the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA), Aurinia Pharmaceuticals, the therapy’s developer, announced. The MHRA’s approval came just a few months after the European Commission approved Lupkynis…

Zetomipzomib as Add-on Therapy Lowers Kidney Inflammation: Data

When given on top of standard therapy, zetomipzomib led to clinically significant reductions in urine protein levels, a marker of kidney impairment, in systemic lupus erythematosus (SLE) patients with active lupus nephritis, a severe form of lupus that causes kidney damage. That’s according to full data from the now…

Itolizumab Shows Promise For Lupus Nephritis Patients in Early Trial Data

Equillium’s investigational antibody-based treatment, itolizumab (EQ001), led to significant reductions in urine protein levels — a marker of kidney dysfunction — in systemic lupus erythematosus (SLE) patients with active lupus nephritis, according to an interim analysis from the type B portion of the Phase 1b EQUALISE clinical trial.

European Commission OKs Lupkynis for Active Lupus Nephritis

The European Commission has approved Lupkynis (voclosporin) to treat active lupus nephritis, a serious complication of systemic lupus erythematosus (SLE) that is characterized by kidney inflammation. The approval is valid in all European Union (EU) member states, as well as Iceland, Liechtenstein, Norway, and Northern Ireland. Lupkynis received a similar…